Inverness Counsel LLC Vertex Pharmaceuticals Inc Transaction History

Inverness Counsel LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $23.7 Million - $26.7 Million	-142,804 Closed	0 $0
Q2 2019 Aug 07, 2019	SELL	$164.61 - $190.37 $10.5 Million - $12.1 Million	-63,502 Reduced 30.78%	142,804 $26.2 Million
Q1 2019 May 09, 2019	BUY	$163.73 - $194.7 $15.2 Million - $18.1 Million	92,891 Added 81.9%	206,306 $38 Million
Q4 2018 Jan 29, 2019	SELL	$151.91 - $192.21 $5.84 Million - $7.39 Million	-38,436 Reduced 25.31%	113,415 $18.8 Million
Q3 2018 Oct 30, 2018	BUY	$167.73 - $192.74 $5.59 Million - $6.42 Million	33,331 Added 28.12%	151,851 $29.3 Million
Q2 2018 Aug 02, 2018	BUY	$145.72 - $169.96 $5.54 Million - $6.47 Million	38,050 Added 47.28%	118,520 $20.1 Million
Q1 2018 May 02, 2018	BUY	$151.6 - $177.13 $12.2 Million - $14.3 Million	80,470 New	80,470 $13.1 Million

1,705

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Inverness Counsel LLC , based on Form 13F filings with the SEC.

Stay updated on Inverness Counsel LLC with notifications on news.